回复:迷迷糊糊的疱疹系列研究----先从感叹开始
今天有个好消息了。 世界上最大的药厂之一 agenus 宣布疱疹疫苗实验已经完成了第一期。 是抑制复发的。
慢慢地,越来越多的药品选择,到时大家就可以选择自己合适的药物了,不用就在洛维里面选, 相信好消息一定会接踵而来。
时间不多,先来一条。
迷糊
Agenus is also involved in development of treatments for infectious diseases, notably genital herpes. Its “Herp V” drug has already cleared Phase 1 trials. The company website describes the drug as a “polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes…” that has completed Phase 1 clinical testing, and consists of “recombinant human heat shock protein-70 complexed with multiple distinct antigens from the HSV-2 proteome.”
The Herp V drug works by stimulating the immune system to create a much higher level of CD4 and CD8 Killer T cells. Such cells have been known to be present at higher levels in people with immunity to the herpes simplex virus (HSV) and tend to remain present near the site of an outbreak for some time after it heals. The same cells have cleared the virus in the spinal cords and neurologic tissue in mice, though it is not yet certain that it can do so in humans.